conceptual framework or perhaps a homogenous product called a computer. That was not a global paradigm shift towards awareness and education with respect to health and wellness. That is not dot-com.
Our own bodies have an endogenous cannabinoid system that we know modulates so many facets of our internal systems including blood glucose and inflammation. We know that the modern diet appears to have caused or advanced what some refer to as an epidemic of inflammation and we know that inflammation is often referred to as the unifying theory of disease. Diabetes is often referred to as a modern epidemic and if that was not bad enough we are seeing that term used to describe Alzheimer’s more and more. We also see an increasing body of study that refers to Alzheimer’s as Type 3 diabetes. Cannabis is showing more and more to be an effective treatment option for diabetes with some advocating that it has the potential to stop the progression or perhaps even reverse the disease. And yes, it should come as no surprise that there appears some preliminary trials that indeed show cannabis having some positive results with respect to the treatment of Alzheimer’s. We published a pioneering hypothesis last summer on this. A lot more research needs to be done of course and we must be just as guarded from hype and confirmation bias as we are from the works of the hucksters and their schemes. The last part is indeed reminiscent of dot.com but the paragraph’s messaging – that is not dot-com.
I can go on and on. You may recall that our industry leading pioneering hypothesis from last summer with respect to inflammation and cannabis + lifestyle was soon followed by our prediction of a rise on pharmacogenomics (personalized medicine or genomics) in this industry. As part of our published work we reached out to industry leaders on both sides of the 49th parallel to see if anyone else had put forth a similar proposition and prediction. The answers were “no”. One of these source was Aleafia Inc in Canada and in late October Aleafia announced they were undertaking research into pharmacogenomics with respect to cannabis. That my friends, is the CannaInvestor Magazine advantage and that is not dot-com.
154